Since anti-PD-1 therapy is mainly targeted at exhausted T cells and other immunosuppressed immune cells, thus a higher fraction of Exhaustionhi T might provide more therapeutic targets, which could explain anti-PD-1 therapy is more effective in HBV+ non-liver cancer patients. The gene discussed is PDCD1; the disease is liver cancer.